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Introduction
The influenza pandemic of 1918/1919 was a unique
event in recorded history, costing on the order of 50 mil-
lion lives in less than a year (Johnson and Mueller, 2002).
Even though this number of deaths was horrendous, the
overall mortality rate for those infected in the U.S. and in
Europe was only about 2%. Thus, a very large percent-
age of the two billion world population became infected
and suffered some degree of illness.
Indirect evidence obtained several decades later sug-
gested that the pathogen responsible for this illness was
an influenza virus belonging to the H1 hemagglutinin
(HA) subtype and that it (or its descendants) continued
to circulate in the human population as well as in pigs.
The first human influenza virus isolates date from
1933, and these H1 viruses circulated until 1957, only
to reappear in 1977 (Nakajima et al., 1978). Except for
this short interruption of 20 years, H1 viruses have
been circulating in the human population since 1918
up until the present and have undergone continuous an-
tigenic change (or ‘‘antigenic drift’’). From 1957 to 1968,
influenza viruses of the H2 subtype were prevalent, and
in 1968, another subtype change occurred when viruses
with an H3 HA appeared (Figure 1).
It is thought that human influenza viruses undergo
a major subtype change (or antigenic shift) by acquiring
novel HA genes from animal (avian) influenza viruses by
reassortment. Because the population has little or no
herd immunity to such a new virus, pandemics or global
epidemics can result. This genetic exchange leading to
a new reassortant most likely occurs when the same
cell is simultaneously infected by a human and an animal
influenza virus and a reshuffling of the segmented RNA
genome of these viruses takes place. Compared to the
1918 pandemic, the pandemics caused by the 1957
(H2N2) and 1968 (H3N2) viruses were relatively mild,
with estimates of one million and half a million deaths
worldwide, respectively, which corresponds to an over-
all mortality rate of less than 0.02% and 0.01%.
Reconstruction of the 1918 Influenza Virus
The advent of reverse genetics techniques for negative-
strand RNA viruses makes it possible to introduce DNA-
derived sequences/genes into influenza viruses (Luytjes
et al., 1989) and to reconstruct infectious influenza vi-
ruses entirely from commercially available oligonucleo-
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done by transfecting into cells (1) expression plasmids
that transcribe the eight RNA segments of the influenza
virus and (2) helper plasmids that express the RNA-de-
pendent RNA polymerase of the virus. Based on the nu-
cleotide sequence that was obtained from RNA frag-
ments present in lung samples of victims of the 1918
influenza virus (Taubenberger et al., 2005), we suc-
ceeded in reconstructing the extinct pandemic virus
(Tumpey et al., 2005). This virus turns out to be highly vir-
ulent in the mouse model, more so than any other human
(i.e., nonmouse-adapted) influenza virus strain tested. It
is also highly pathogenic for chicken embryos, capable
of killing these embryos at very low doses (less than
100 tissue culture infectious particles). Finally, the virus
is also able to grow in human tissue culture cells to high
titers (almost 109 plaque-forming units/ml, which is a ten
times higher titer than that observed for other human in-
fluenza viruses), and it can replicate in cells in the ab-
sence of trypsin, which may also indicate high virulence
(Tumpey et al., 2005).
Questions for the Immunologist
What Is the Immunological Basis for the W Shaped
Curve of Case Fatality Rates in the 1918 Influenza Pan-
demic? One of the benefits of having the 1918 influenza
virus ‘‘in hand’’ is that we can begin to study in the lab-
oratory the mechanisms that may have contributed to
the high morbidity and mortality associated with the
1918 pandemic. Based on the experiments performed
so far, the 1918 virus is indeed unusually virulent and
certainly seems to be a real ‘‘winner’’ as far as replica-
tion is concerned. In 1918, two age groups had an un-
usually high case fatality rate as a result of influenza: the
very young (less than 1 year) and healthy young adults
(ages 25–35). Interestingly, the mortality rate dropped
beyond about age 35, only to again rise in people older
than 65 years (Figure 2). This W shaped curve is un-
usual and is not seen in pre-1918 years. For example, in
1915, a U shaped curve for mortality is observed (with
few fatalities in the age group 5–50). Such U shaped
curves are typical for previously exposed populations,
and indeed, most interpandemic years follow a U
shaped distribution. The high mortality W shape for the
1918 virus may result from the combined effects of (1)
the intrinsically greater virulence of the virus (as com-
pared to other pandemic influenza viruses) and (2) the
fact that it struck a population that was mostly immuno-
logically naı¨ve (Zamarin and Palese, 2003; Palese,
2004). This hypothesis further suggests that the virus
might have been even more devastating (i.e., to the
35–65 age group) had there not been a similar H1-like
virus in circulation before 1889. This may have provided
partial crossprotection in the older age group born be-
fore 1889. Without this prior exposure of the older pop-
ulation, the case fatality rate for the 1918 pandemic
would have followed a V shaped curve, with many
more adults dying or becoming seriously ill.
What Are the Factors Determining a V Shaped Curve
for Fatality Rates? Most lytic virus infections in immuno-
logically naive humans have such a V shaped curve of
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122Figure 1. Influenza A Virus Subtypes Circu-
lating in the Human Population
Currently H1N1 (hemagglutinin, subtype 1;
neuraminidase, subtype 1) and H3N2 sub-
types are prevalent. From 1957 to 1968,
H2N2 viruses circulated, and before that,
starting in 1918, H1N1 strains were observed.
The broken line indicates that no isolates are
available. H1 subtype strains are postulated
to have circulated until 1889, and indirect ev-
idence (Dowdle, 1999) suggests that H3
strains were subsequently introduced.case fatality rates (and/or serious complications) when
plotted against age groups. For example, the case fatal-
ity rate of measles on the Faroe islands in 1846 (when
measles virus was not endemic) follows a V like shape
with a trough in the 10–19 year group. Infants under
1 year of age and adults between 40 and 49 years had
a more than 100-fold and 15-fold higher mortality rate, re-
spectively, due to measles than the group 10–19 years
(http://www.deltaomega.org/PanumFaroeIslands.pdf).
Another example concerns infections by smallpox virus.
Again, in immunologically naive populations, the mortal-
ity rates follow a V like shape, as was discovered when
the indigenous populations of the Americas first came
into contact with viral agents brought to the Western
hemisphere by the Europeans. A recent manifestation
of the V shaped curve of viral infection in an immunolog-
ically naive host is the smallpox vaccination program.
This biodefense-driven program had to be discontinued
Figure 2. Specific Death Rates Caused by Influenza/Pneumonia for
1915 and 1918 in the United States
U and W shaped curves for influenza/pneumonia deaths for the years
1915 and 1918, respectively. Specific death rate is for 100,000 per-
sons in the age group indicated (Linder and Grove, 1947). It is hy-
pothesized that a V shaped curve would have been observed had
the entire population in 1918 been immunologically naı¨ve (dotted
line).because of the number of serious complications occur-
ring in immunologically naive age groups older than chil-
dren (trough of the curve).
Does the group of 5–14 year olds possess a better
innate immune response against influenza viral infec-
tions than younger or older individuals? Are there age-
dependent mechanisms involving clonal exhaustion
of T cell responses during viral infections (Welsh and
McNally, 1999)? These are general questions that should
be asked (and hopefully answered) for influenza and for
many other viral diseases, including measles, mumps,
poliomyelitis, and smallpox.
Was There Immune Memory in the Population of 1918?
Was there indeed a partial immune protection against in-
fluenza H1 subtype viruses in the population born before
1889? Two pieces of indirect evidence support such
a hypothesis. First, when in 1977 an H1N1 virus reap-
peared that was genetically very similar to strains circu-
lating in 1950 (Nakajima et al., 1978), people younger
than 25 years of age were most affected, suggesting
that there may be long-lasting immunity in people who
were infected by an earlier virus. Second, mice chal-
lenged with viruses carrying the 1918 HA and neuramin-
idase (NA) were shown to be largely protected from
death by prior immunization with a vaccine containing
the current H1N1 component (Tumpey et al., 2004).
This experiment suggests that in mice partial immune
protection can be achieved by immunizing with a virus
belonging to the same subtype. Thus, we should ask
whether current preexisting immunity in humans may
preclude the outbreak of a highly virulent 1918-like H1
virus (the same question could be asked about H3N2
viruses, to which we also have antibodies). Can we
develop new quantitative measurements (immune surro-
gate markers) that go beyond the classical hemaggluti-
nation inhibition tests in identifying the immune status
of the individual?
Does Recycling of HA Subtypes Occur? If indeed H1-like
viruses were prevalent before 1889 (see above) and H3-
like viruses before 1918 (Dowdle, 1999), we need to try
to understand how influenza viruses (or influenza virus
genes) recycle in such a way that viruses with similar
antigenic makeup occasionally reappear. It is possible
that human influenza viruses recur once the herd immu-
nity in humans wanes and that these human viruses are
circulating in animals in the meantime. This hypothesis
might be explored by more intense surveillance of influ-
enza viruses, involving not only avian species but also
other species as well. This should also include a better
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different avian species to (influenza) virus infections. In
addition, samples from human cadavers and animal
species should be further examined for the presence
of influenza virus RNAs, and their sequences should
be obtained and compared with sequences of other in-
fluenza viruses, including that of the 1918 strain. In this
context, it should be noted that more than 28 million nu-
cleotides were recently sequenced from material ob-
tained from a Siberian woolly mammoth that died more
than 25,000 years ago (Poinar et al., 2005). This was
achieved by a novel emulsion polymerase chain reaction
and pyrosequencing technique. Such sequencing tech-
niques may help in identifying influenza viruses from dif-
ferent species and from earlier time periods. Based on
this information, the question of recycling of HA sub-
types may be more fully answered in the future.
Does the Influenza Viral Antagonist of the Innate Immune
System Affect Species Specificity and Tissue Tropism?
Experiments with influenza viruses lacking the NS1
gene have shown that the NS1 protein has interferon an-
tagonist activity (Garcia-Sastre et al., 1998). Analysis of
the NS1 protein of the 1918 virus suggests that the
1918 virus-derived NS1 protein shows optimal activity
in human cells (Basler et al., 2001; Tumpey et al.,
2004). Is it possible that the NS1 proteins of different
strains determine differential virulence in one species
versus another? Another question concerns the restric-
tion of influenza virus infections to the respiratory tract.
Might this be because respiratory cells are less likely to
react to viral infections by a vigorous antiviral (interferon)
response, so as not to induce a highly inflammatory and
thus detrimental response in the respiratory tract? Non-
respiratory tissue would induce a more vigorous cyto-
kine response (innate immune response) and thus, in
most instances, prevent a transfer of influenza viruses
to other tissues/organs.
Which Factors Influence the Pathophysiology of Influ-
enza Virus Infections? Which factors in a virulent virus
such as the 1918 virus determine whether the host is
able to mount a beneficial immune response or whether
its response leads to a detrimental cytokine storm (Ko-
basa et al., 2004)? What determines the well-known clin-
ical symptoms of myalgia at sites where no virus replica-
tion can be detected? Very little is understood about the
mechanism leading to this manifestation. Even the phe-
nomenon of ‘‘antigenic sin’’ (i.e., the specific immune
recall response to earlier influenza virus strains after in-
fection or vaccination with later variants) is not well
understood (Gulati et al., 2005). The generation and
maintenance of memory, both for humoral immunity as
well as for memory T cells (Masopust et al., 2004), re-
mains an intensely studied topic in immunology. Study-
ing the mechanisms of memory in humans will be impor-
tant for understanding the disease outcome of influenza
and for improving vaccine designs against the ever
changing virus.
Last, but not least, major efforts will have to be made to
better understand the parameters determining transmis-
sion. The 1918 virus had an unusual ability to transmit
from human to human. At the other end of the spectrum
are the H5N1 viruses, which cause devastation in poultry
and can also be transmitted to humans, with more than
70 human deaths having been reported (http://www.who.int/csr/disease/avian_influenza/country/en/). How-
ever, these H5N1 strains are not effectively transmitted
from person to person. Thus, it will be important to define
the immunological and pathophysiological characteris-
tics of a strain (gene) that determine transmission in
humans.
Universal Influenza Virus Vaccines? It has been shown
that mice can be protected against influenza viruses
containing the 1918 HA and NA by using conventional
vaccine methodologies (Tumpey et al., 2004). It has
also been shown that the 1918 virus possesses an NA
and an M2 protein that make it sensitive to the FDA-ap-
proved NA inhibitors and amantadines, respectively
(Tumpey et al., 2002). Thus, there are tools available to
attenuate influenza virus infections. However, because
of logistical and financial constraints associated with
the use of antivirals and because of the emergence of re-
sistance (de Jong et al., 2005; Le et al., 2005), the only re-
alistic public health measure against both epidemic and
pandemic influenza is vaccination. The currently avail-
able technology would allow the development of effec-
tive vaccines, if industry could be given sufficient incen-
tives and the regulatory agencies would be willing to
embrace newer technologies, including the use of tissue
culture, adjuvants, and reverse genetics (Fauci, 2006).
The challenge in the short run will be to facilitate rapid
public health responses by developing sufficient indus-
trial capacity and providing the right regulatory and
commercial climate to allow unencumbered use of the
vaccine. In the long run, we will have to address even
more complex challenges. One direction to explore is
the development of crossreactive vaccines that would
protect against strains resulting from antigenic drift.
Could this be achieved by selecting monoclonal anti-
bodies that are highly crossreactive and then identifying
the epitopes responsible for such reactivities? We might
be able to then base future crossreactive vaccines on
these epitopes. Could vaccines based on cellular im-
mune responses that are made longer lasting be a solu-
tion for developing crossreactive (universal) vaccines?
Or will completely new approaches, which do not build
on any present-day techniques (or adjuvants), be neces-
sary? Another approach may be directed at developing
vaccines that could be effective against viruses of all
known 16 HA subtypes (Fouchier et al., 2005). Are there
structural elements shared by all HAs (NAs) that could
serve as the basis for a universal vaccine? Would (local)
interferon inducers (immune enhancers) be a solution
rather than specific vaccine preparations? Can we hope
for the introduction of new and safe adjuvants that go
beyond the effectiveness of those currently being used
(and which may allow for the immune induction of uni-
versal epitopes)? The synergistic knowledge of virolo-
gists and immunologists as well as geneticists should
bring us novel medical interventions (Nabel, 2004) and
advances in the field of vaccines.
Conclusion
The influenza pandemic of 1918/1919 was a unique
event, and reconstructing the virus has helped us to be-
gin understanding why the virus was extraordinarily vir-
ulent and what contributed to the unusual mortality
pattern in the population. Questions still need to be
answered as to how the 1918 virus and other influenza
viruses interact with the innate immune system, and
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tively measuring immune parameters after infections
and leading to protection. These include both cellular
and humoral immune responses. The availability of the
1918 virus will help us to understand the mechanisms
by which pandemic influenza viruses are transmitted
from human to human and from one species to another.
Efforts underway in many laboratories will effectively ex-
pand our knowledge of the biological and molecular
properties of pandemic influenza viruses, and this re-
search will provide us with better preventions and treat-
ment strategies for the future.
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